Rubosixtaurin and other pkc inhibitors in diabetic retinopathy and macular Edema. Review

Current Diabetes Reviews

Volumn 5, Issue 1, 2009, Pages 14-17

  Gálvez, M Isabel López ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MIDOSTAURIN; PLACEBO; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLATULENCE; GLYCEMIC CONTROL; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; VISUAL IMPAIRMENT; DRUG ANTAGONISM; HYPERGLYCEMIA; NEOVASCULARIZATION (PATHOLOGY); RETINA MACULA EDEMA;

DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; HYPERGLYCEMIA; INDOLES; MACULAR EDEMA; MALEIMIDES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C;

EID: 65549122820     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909787314167     Document Type: Review

References (31)

1. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26(9): 2653-64.
2. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS Report No 9. Ophthalmology 1991; 98(Suppl.): 766-85.
4. Aiello LLP. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136(6): 122-35.
5. Polak B, Dekker JM, Moll AC, Van Leiden H.A. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136(6): 1193.
6. American Diabetes Association. Implications of the United Kingdom Propesctive. Diabetes Study. Position Statement. Diabetes Care 2002; 25: 28-32.
7. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
8. Girault J-A. Protein phosphorylation and dephosphorylation in mammalian central nervous system. Neurochem Int 1993; 23: 1-25.
9. Frank RN. Potential new medical therapies for diabetic retinopathy. Protein Kinase C Inhibitors. Am J Ophthalmol 2002; 133: 693-8.
10. Donnelly R, Idris I, Forrester JV. Protein Kinase C inhibition and diabetic retinopathy: a shot in the dark at transalational research. Br J Ophthalmol 2004; 88: 146-51.
11. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332: 281-92.
12. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophtalmol 2002; 47(2): S263-9.
13. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediatedby protein kinase C in vivo and suppressed by an orally effective β-isoform selective inhbitor. Diabetes 1997; 46: 1473-80.
14. Wenberg LA. Proximal signaling molecules as potential targetsfor antiinflammatory theraphy. Curr Opin Drug Discov Dev 2007; 10: 560-64.
15. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4, 9:16,21-dimeth eno-1H,13H-dibenzo i e,k]pyrrolo [3,4-h] [1,4,13]-oxadiazacyclohexa decene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of proteinkinase Cβ. J Med Chem 1996; 39: 2664-71.
16. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int J Cancer 1989; 43: 851-6.
17. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Ocular manifestations of systemic disease. Curr Opin Ophthalmol 2005; 15(6): 508-18.
18. Propper DJ, McDonald A, Man P, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
19. Peter A. Campochiaro1 and The C99-PKC412-003 Study Group. Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412. Invest Ophthalmol Vis Sci 2004; 45: 922-31.
20. Ishii H, Jirousek M, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCb inhibitor. Science 1996; 272: 728-31.
21. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 2001; 39: 171-9.
22. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
23. Kirk Ways D. Protein Kinase C beta and chronic complications of diabetes. Diabetes Rev Int 1998; 7: 9-12.
24. Donnelly R. Protein Kinase C. A novel therapeutic target in microvascular complications. Mod Diabetes Manage 2000; 1: 13-16.
25. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase Cβ inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-18.
26. Aiello LP, Bursell SE, Devries T, Alatorre C, King GL, Ways DK. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes- induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47: 86-92.
27. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the PKC-DRS multicenter randomized clinical trial. Diabetes 2005; 54: 2188-97.
28. Gardner TW, Antonetti, DA. Ruboxistaurin for diabetic retinopathy. Ophthalmology 2006; 113: 2135-6.
29. PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113: 2221-30.
30. The PKC- DMES study group. Thirty-Month Resultsof the Randomized PKC-DMES Clinical Trial. Effect of Ruboxistaurin in Patients With Diabetic Macular Edema. Arch Ophthalmol 2007; 125: 318-24.
31. Lilly announces FDA requirement of additional clinical trial before ruboxistaurin could be approved for treatment of diabetic retinopathy. Available at: http://newsroom.lilly.com. Accessed October 5, 2006.